Breaking News, Collaborations & Alliances

FMI, WuXi PharmaTech Enter Genomic Profiling Pact

WuXi to perform FoundationOne assay at Shanghai Genome Center

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Foundation Medicine, Inc. (FMI) and WuXi PharmaTech (Cayman) Inc. have entered a collaboration to offer Foundation Medicine’s genomic profiling to biopharma companies conducting clinical trials in China.   FMI will license WuXi to perform the lab component of its FoundationOne assay at WuXi’s Genome Center in Shanghai. FMI will offer China-based products and services to support clinical R&D efforts in China. Financial terms were not disclosed.   “China is poised to become the second-largest ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters